Target Name: CCNB1IP1
NCBI ID: G57820
Review Report on CCNB1IP1 Target / Biomarker Content of Review Report on CCNB1IP1 Target / Biomarker
CCNB1IP1
Other Name(s): cyclin B1 interacting protein 1 | CCNB1IP1 variant 1 | CCNB1IP1 variant 2 | E3 ubiquitin-protein ligase CCNB1IP1 | HEI10 | Enhancer of invasion 10 | human enhancer of invasion 10 | Human enhancer of invasion 10 | Cyclin B1 interacting protein 1, transcript variant 2 | Cyclin-B1-interacting protein 1 | C14orf18 | epididymis secretory sperm binding protein | Cyclin B1 interacting protein 1, E3 ubiquitin protein ligase, transcript variant 1 | RING-type E3 ubiquitin transferase CCNB1IP1 | cyclin B1 interacting protein 1, E3 ubiquitin protein ligase | CIP1_HUMAN

CCNB1IP1: A Potential Drug Target and Biomarker for Cancer

Introduction

Cyclin B1 (CCNB1) is a key regulator of cell cycle progression and has been implicated in various diseases, including cancer. The interaction of CCNB1 with its protein partners, known as cyclin-dependent kinases (CDKs), has been extensively studied, and several Kinases have been identified as potential drug targets or biomarkers. One such protein is CCNB1IP1, which is a potential drug target and biomarker for cancer.

CCNB1IP1: A Putative Drug Target

The CCNB1IP1 protein is a 21-kDa protein that is expressed in various tissues and has been shown to interact with CCNB1. It is a component of the nuclear envelope, which surrounds the cytoplasm and is involved in regulating the delivery and excretion of proteins into the cell. The interaction between CCNB1 and CCNB1IP1 has been shown to play a role in regulating cell proliferation and apoptosis, suggesting that it may be a potential drug target for cancer.

Drugs that target CCNB1IP1 have the potential to inhibit its activity and disrupt its role in cell proliferation. This could lead to a reduction in the number of cancer cells that divide and proliferate, leading to a decrease in cancer-related symptoms and a reduced risk of disease progression.

CCNB1IP1 as a Biomarker

In addition to its potential as a drug target, CCNB1IP1 has also been identified as a potential biomarker for cancer. The expression of CCNB1IP1 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that CCNB1IP1 may be a useful biomarker for cancer diagnosis and monitoring.

The ability to diagnose and monitor cancer through the expression of specific proteins is a promising approach to the development of new cancer treatments. If CCNB1IP1 is indeed a reliable biomarker for cancer, it has the potential to improve the accuracy and effectiveness of cancer diagnostics and treatments.

Conclusion

In conclusion, CCNB1IP1 is a putative drug target and biomarker for cancer. Its interaction with CCNB1 has been shown to play a role in regulating cell proliferation and apoptosis, making it a potential target for cancer therapies. Further research is needed to confirm its potential as a drug and to explore its potential as a biomarker for cancer. If its potential as a drug target and biomarker is confirmed, CCNB1IP1 has the potential to become a valuable tool in the fight against cancer.

Protein Name: Cyclin B1 Interacting Protein 1

Functions: Ubiquitin E3 ligase that acts as a limiting factor for crossing-over during meiosis: required during zygonema to limit the colocalization of RNF212 with MutS-gamma-associated recombination sites and thereby establish early differentiation of crossover and non-crossover sites. Later, it is directed by MutL-gamma to stably accumulate at designated crossover sites. Probably promotes the dissociation of RNF212 and MutS-gamma to allow the progression of recombination and the implementation of the final steps of crossing over (By similarity). Modulates cyclin-B levels and participates in the regulation of cell cycle progression through the G2 phase. Overexpression causes delayed entry into mitosis

The "CCNB1IP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNB1IP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248